Post-lumpectomy Radiation Therapy Boost in Breast Cancer Patients: Evidence Revisited

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2021 Apr 23

PMID 33889203

Citations 2

Authors

Majd Kayali

Joseph Abi Jaoude

Paul Ramia

Hazem Assi

Fady Geara

Philip Poortmans

Youssef H Zeidan

Affiliations

Soon will be listed here.

Abstract

Purpose: Radiation therapy is an integral part in the management of breast cancer after breast conservative surgery. In selected patients at high risk for local recurrence (LR), a boost radiation dose is commonly applied to the tumour bed.

Methods: We performed a review of the English literature using PubMed, Medline and Google Scholar for published manuscripts addressing the effect of boost radiation in breast cancer patients, focusing mainly on LR and overall survival (OS).

Results: A total of seven studies were included in our review. Most studies (6/7, 85.7%) showed a significant improvement in local control independent of age (hazard ratios ranging between 0.34 and 0.73), with the largest absolute benefit in younger patients. None of the studies, however, was able to demonstrate an improvement in OS.

Conclusions: With lack of sufficient studies addressing the role of boost radiation, individualised treatment decisions are recommended, taking into account the risk factors for LR, including tumour biology. Real-life data are sorely needed to better assess the role of tumour bed boost in the contemporary era.

Citing Articles

The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy.

Arenas M, Bolukbasi Y, Boersma L, Offersen B, Kouloulias V, Palumbo I Breast. 2025; 80:103881.

PMID: 39854807 PMC: 11804728. DOI: 10.1016/j.breast.2025.103881.

Integrating Radioprotective Agents into Post-Mastectomy Radiotherapy: Optimization of Reconstructive Outcomes in Breast Cancer.

Ramachandran N, Ayoub N, Agrawal D J Surg Res (Houst). 2024; 7(4):454-465.

PMID: 39605991 PMC: 11600463. DOI: 10.26502/jsr.10020395.

Expert Discussion: Hypofractionated Radiation Therapy - Standard for All Indications?.

Fastner G, Krug D, Meattini I, Gruber G, Poortmans P Breast Care (Basel). 2022; 17(2):224-231.

PMID: 35707177 PMC: 9149542. DOI: 10.1159/000521552.

References

Brouwers P, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J . Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. Radiother Oncol. 2018; 128(3):434-441. DOI: 10.1016/j.radonc.2018.06.020. View

Zhou P, Recht A . Young age and outcome for women with early-stage invasive breast carcinoma. Cancer. 2004; 101(6):1264-74. DOI: 10.1002/cncr.20523. View

Fastner G, Sedlmayer F, Merz F, Deutschmann H, Reitsamer R, Menzel C . IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol. 2013; 108(2):279-86. DOI: 10.1016/j.radonc.2013.05.031. View

Zeidan Y, Habib J, Ameye L, Paesmans M, de Azambuja E, Gelber R . Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018; 101(2):316-324. DOI: 10.1016/j.ijrobp.2018.01.105. View

Schreuder K, Maduro J, Spronk P, Bijker N, Poortmans P, van Dalen T . Variation in the Use of Boost Irradiation in Breast-Conserving Therapy in the Netherlands: The Effect of a National Guideline and Cofounding Factors. Clin Oncol (R Coll Radiol). 2018; 31(4):250-259. DOI: 10.1016/j.clon.2018.11.033. View

Franco P, Cante D, Sciacero P, Girelli G, La Porta M, Ricardi U . Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence. Breast Care (Basel). 2015; 10(1):44-9. PMC: 4395817. DOI: 10.1159/000369845. View

Lemanski C, Azria D, Thezenas S, Gutowski M, Saint-Aubert B, Rouanet P . Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys. 2006; 64(5):1410-5. DOI: 10.1016/j.ijrobp.2005.10.025. View

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A . Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002; 347(16):1227-32. DOI: 10.1056/NEJMoa020989. View

Polgar C, Fodor J, Orosz Z, Major T, Takacsi-Nagy Z, Mangel L . Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial. Strahlenther Onkol. 2002; 178(11):615-23. DOI: 10.1007/s00066-002-1053-1. View

10.

Pu Y, Mao T, Zhang Y, Wang S, Fan D . The role of postmastectomy radiation therapy in patients with immediate prosthetic breast reconstruction: A meta-analysis. Medicine (Baltimore). 2018; 97(6):e9548. PMC: 5944685. DOI: 10.1097/MD.0000000000009548. View

11.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

12.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

13.

Kyndi M, Sorensen F, Knudsen H, Overgaard M, Nielsen H, Overgaard J . Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26(9):1419-26. DOI: 10.1200/JCO.2007.14.5565. View

14.

van Werkhoven E, Hart G, van Tinteren H, Elkhuizen P, Collette L, Poortmans P . Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. Radiother Oncol. 2011; 100(1):101-7. DOI: 10.1016/j.radonc.2011.07.004. View

15.

Warren L, Miller C, Horick N, Skolny M, Jammallo L, Sadek B . The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014; 88(3):565-71. PMC: 3928974. DOI: 10.1016/j.ijrobp.2013.11.232. View

16.

Millar E, Graham P, OToole S, McNeil C, Browne L, Morey A . Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009; 27(28):4701-8. DOI: 10.1200/JCO.2008.21.7075. View

17.

Bartelink H, Horiot J, Poortmans P, Struikmans H, Van den Bogaert W, Fourquet A . Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22):3259-65. DOI: 10.1200/JCO.2007.11.4991. View

18.

Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A . De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?. Int J Radiat Oncol Biol Phys. 2020; 108(4):1040-1046. DOI: 10.1016/j.ijrobp.2020.06.078. View

19.

Litiere S, Werutsky G, Fentiman I, Rutgers E, Christiaens M, Van Limbergen E . Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012; 13(4):412-9. DOI: 10.1016/S1470-2045(12)70042-6. View

20.

Cameron D, Piccart-Gebhart M, Gelber R, Procter M, Goldhirsch A, de Azambuja E . 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389(10075):1195-1205. PMC: 5465633. DOI: 10.1016/S0140-6736(16)32616-2. View